2. >>Business Strategy

Exclusive Interview: Biopharma And A Biden Administration

An Interview With Greg Simon, Former Executive Director Of The Obama Administration’s Cancer Moonshot Initiative

 
• By Ben Comer

A Biden administration, if elected, would protect biopharmaceutical innovation, tackle the rising costs of cancer drugs and “promote science, without politics.”

Voting booth with American flag
• Source: Shutterstock

The top two health care priorities for US presidential candidate and former Vice President Joe Biden, should he win the election, would be to implement a national COVID-19 plan, and to protect insurance coverage for Americans, said Greg Simon, a former Biden political aid. A “reinvigoration” of the Cancer Moonshot program, and dealing with drug pricing, could be next on Biden’s list. Simon spoke with In Vivo about his personal experiences; he is not officially part of Biden’s 2020 presidential campaign.

PDUFA And Gene Therapy: Bring ‘Fully Baked’ Ideas And ‘Don’t Be Stingy,’ Grogan Tells Developers

Former chief of White House Domestic Policy Council advises cell and gene therapy companies on strategies for promoting enhanced FDA review capabilities as part of Prescription Drug User Fee Act reauthorization negotiations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Deals Shaping The Industry, June 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.